darapladib inhibitor lipoproteinassociated phospholipase development drug treatment discovered human genome sciences collaboration glaxosmithkline november gsk announced drug failed meet phase iii endpoints trial patients acute coronary syndrome additional trial patients solidtimi finished may study failed reduce risk coronary heart disease death myocardial infarction urgent coronary revascularization compared placebo acute coronary syndrome patients treated standard medical darapladib found inhibit intraerythrocytic development malaria parasite plasmodium falciparum inhibition human host enzyme peroxiredoxin authors present data original target darapladib absent host red blood cell drug article relating cardiovascular system stub help wikipedia expanding ithttpsenwikipediaorgwikidarapladib